317 related articles for article (PubMed ID: 35489737)
1. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
2. Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
5. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
6. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
9. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma.
Al-Halabi H; Nantel A; Klekner A; Guiot MC; Albrecht S; Hauser P; Garami M; Bognar L; Kavan P; Gerges N; Shirinian M; Roberge D; Muanza T; Jabado N
Acta Neuropathol; 2011 Feb; 121(2):229-39. PubMed ID: 21107850
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
11. Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation.
Chen Z; Ioris RM; Richardson S; Van Ess AN; Vendrell I; Kessler BM; Buffa FM; Busino L; Clifford SC; Bullock AN; D'Angiolella V
Cell Death Differ; 2022 Oct; 29(10):1955-1969. PubMed ID: 35379950
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
13. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
14. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract][Full Text] [Related]
15. A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma.
Chiang J; Moreira DC; Pytel NJ; Liu YC; Blackburn PR; Shi Z; Cardenas M; Wheeler DA; Furtado LV
Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12815. PubMed ID: 35320876
[TBL] [Abstract][Full Text] [Related]
16. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
Menyhárt O; Győrffy B
Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698
[TBL] [Abstract][Full Text] [Related]
17. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
[TBL] [Abstract][Full Text] [Related]
18. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
19. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
